An observational study in Hypohidrotic Ectodermal Dysplasia, sponsored by University Hospital Erlangen. Completed at 1 site in Germany. Per ClinicalTrials.gov, last updated 2021-08-16.
Sponsored by University Hospital Erlangen · Observational
Longitudinal study of 56 households with at least one member who had COVID-19 to compare the course of illness, immune responses, and long-term consequences of SARS-CoV-2 infection in HED patients with those of control subjects of the same age group. Complete households are investigated, including women who are pregnant when exposed to the virus and their newborn child(ren).
21 studies on the registry are indexed under Ectodermal Dysplasia 1, Anhidrotic; 1 is open to participants now.
This study's enrollment of 231 is above the median of 33 across 16 observational studies indexed under Ectodermal Dysplasia 1, Anhidrotic.
Browse Ectodermal Dysplasia 1, Anhidrotic studies →University Hospital Erlangen is the lead sponsor of 28 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
households with children and/or adolescents and at least one member who has or had a SARS-CoV-2 infection
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
all household members with hypohidrotic ectodermal dysplasia (HED), a rare hereditary developmental disorder
individuals of the same age group, but without HED, including pregnant women
age-dependence of SARS-CoV-2 infection
registry of household members with and without symptoms of COVID-19 (entire households)
Time frame: 3 months from the point in time at which the first household member shows symptoms of COVID-19
percentage of household members infected by SARS-CoV-2
The infection rate is determined on the basis of specific PCR tests and detectibility of antibodies against SARS-CoV-2.
Time frame: 3 months from the point in time at which the first household member shows symptoms of COVID-19
duration of primary COVID-19 symptoms
The possible association between the length of time with symptoms of COVID-19 and specific immune responses, in particular the development of virus-neutralizing antibodies, is studied.
Time frame: 2 months from the onset of COVID-19 symptoms
frequency of late-onset cardiovascular complications
Patient-reported known and yet unknown long-term consequences of COVID-19 are registered and investigated further (questionnaire, specific data confirmed by clinical examination).
Time frame: 2-12 months from the onset of COVID-19 symptoms
frequency of postviral fatigue
Patient-reported symptoms of fatigue are registered (questionnaire).
Time frame: 2-12 months from the onset of COVID-19 symptoms
frequency of noticeable temporary hair loss after COVID-19
Patient-reported extent of hair loss is registered (questionnaire).
Time frame: 2-12 months from the onset of COVID-19 symptoms
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ectodermal Dysplasia 1, Anhidrotic →
University Hospital Erlangen